Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Feb 10;188(2):163.
doi: 10.1093/bjd/ljac080.

Safety of baricitinib in patients with alopecia areata

Robert Bissonnette  1
Affiliations
Comment

Safety of baricitinib in patients with alopecia areata

Robert Bissonnette. Br J Dermatol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: R.B. is an advisory board member, consultant, speaker and/or investigator for and receives honoraria and/or grants from AbbVie, Almirall, Alumis, Amgen, AnaptysBio, Arcutis, Arena Pharma, Asana BioSciences, Bausch Health, Bellus Health, BioMimetix, Bluefin Biomedicine, BMS, Boehringer-Ingelheim, Boston, Brickell, CARA Therapeutics, Clexio, Concert, Dermavant, Eli Lilly, Evidera, Galderma, GlaxoSmithKline, Horizon, Incyte, Inmagene Bio, Janssen, Kyowa Kirin, LEO Pharma, Nimbus, Novartis, Pfizer, RAPT Therapeutics, Respivant, Sanofi, Target RWE, UCB, VentyxBio, Vyne Therapeutics and Xencor. R.B. is also an employee and shareholder of Innovaderm Research.

Comment on

  • Two Phase 3 Trials of Baricitinib for Alopecia Areata.
    King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, Hordinsky M, Dutronc Y, Wu WS, McCollam J, Chiasserini C, Yu G, Stanley S, Holzwarth K, DeLozier AM, Sinclair R; BRAVE-AA Investigators. King B, et al. N Engl J Med. 2022 May 5;386(18):1687-1699. doi: 10.1056/NEJMoa2110343. Epub 2022 Mar 26. N Engl J Med. 2022. PMID: 35334197 Clinical Trial.

MeSH terms

Supplementary concepts

LinkOut - more resources